Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
OHSU Knight Cancer Institute
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06504459CT.gov Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | — | Recruiting | — | — | — |
NCT05313958CT.gov Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Monocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cladribine (this asset) | OHSU Knight Cancer Institute | P2/3 | BB · 64 |
| Etoposide | Stanford University | P3 | BBB |
| Cytarabine | Chinese PLA General Hospital | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | ECOG-ACRIN Cancer Research Group | P3 | BBB |
| Nivestim | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BBB |
| Mitoxantrone | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P2/3 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BBB |
| Idarubicin | Chinese PLA General Hospital | P3 | BBB |
+41 more in the Acute Monocytic Leukemia cohort
Other indications for Cladribine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 76 |
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Multiple Sclerosis | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cladribine in Acute Monocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cladribine-acute-monocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →